Synthetic nanoparticles functionalized with cell membrane-mimicking, bone-targeting, and ROS-controlled release...

Area of Science:

• Biomaterials Science
• Nanotechnology
• Osteoporosis Research

Background:

• Postmenopausal osteoporosis is a prevalent degenerative bone disease with limited therapeutic options.
• Current treatments for osteoporosis often lack specificity and exhibit diverse targets.
• There is a need for innovative therapeutic strategies to address the challenges in osteoporosis management.

Purpose of the Study:

• To synthesize and characterize a novel nanoparticle, ALN@BMSCM@PLGA-TK-PEG-SS31, for osteoporosis treatment.
• To evaluate the nanoparticle's ability to target bone tissue and mitigate oxidative stress.
• To assess the therapeutic efficacy of the nanoparticle in vitro and in vivo models of osteoporosis.

Main Methods:

• Synthesis of a core nanoparticle (PLGA-TK-PEG-SS31) coated with bone marrow mesenchymal stem cell membranes (BMSCMs) and incorporating DSPE-PEG-ALN.
• Evaluation of nanoparticle size, ROS-triggered drug release, and immune evasion capabilities.
• In vitro studies assessing inhibition of osteoclastogenesis and promotion of osteogenic differentiation.
• In vivo studies using an ovariectomy-induced osteoporosis mouse model to evaluate therapeutic effects.

Main Results:

• The synthesized nanoparticle (ALN@BMSCM@PLGA-TK-PEG-SS31) demonstrated effective bone targeting and evasion of immune phagocytosis.
• The nanoparticle successfully downregulated reactive oxygen species (ROS) generation in bone tissue.
• In vitro, the nanoparticle inhibited osteoclastogenesis and promoted osteogenic differentiation.
• In vivo, the nanoparticle significantly increased bone mass and ameliorated oxidative stress in an osteoporosis mouse model without notable side effects.

Conclusions:

• ALN@BMSCM@PLGA-TK-PEG-SS31 exhibits dual therapeutic effects, addressing both bone resorption and formation.
• The nanoparticle's design facilitates targeted delivery, ROS scavenging, and enhanced bone regeneration.
• This novel nanoparticle represents a promising therapeutic candidate for managing postmenopausal osteoporosis.